IN RE: RISPERDAL® LITIGATION

Plaintiff(s),

ν.

Janssen Pharmaceuticals, Inc.; Johnson & Johnson; and Janssen Research & Development, LLC; Excerpta Medica, Inc.; and Elsevier Inc.,

Defendants.

PHILADELPHIA COUNTY COURT OF COMMON PLEAS TRIAL DIVISION

MARCH TERM 2010

No. 296

DOCKETED COMPLEX LIT CENTER

MAY 2 2014

J. STEWART

ORDER

ND NOW, this day of

4, 2014, upon consideration of Defendants

Janssen Pharmaceuticals, Inc.; Johnson & Johnson; and Janssen Research & Development,

LLC's Motion for Partial Summary Judgment as to Plaintiffs' Claims for Punitive Damages

(Count XI), and the response of Plaintiffs, if any, it is **ORDERED** that motion is **GRANTED**.¹

BY THE COURT:

Árnold New, J.

In Re: Risperdal Litiga-ORDER

10030029600139

Cantral #14021436

¹ This Court finds that New Jersey law applies to the issue of punitive damages. Pursuant to the New Jersey Products Liability Act and controlling New Jersey case law, New Jersey law does not permit Plaintiffs to recover punitive damages.